| HRA005229
(Controlled Access)
|
Tumor-specific antigens (TSAs) are highly desirable targets for cancer immunotherapy. However, current clinical studies have predominantly focused on neoantigens present in exon regions, while the limited number of TSAs identified from coding regions has impeded the development and application of immunotherapy. Here, we developed a proteogenomic approach that integrates multi-omics data from the whole genome, transcriptome, and immunopeptidome to globally discover TSAs. |
